Results 61 to 70 of about 9,340 (184)

IL‐33 Drives Inflammatory Changes and Extracellular Trap Formation in Eosinophils Involving Oxidised LDL and Complement Pathways

Allergy, EarlyView.
IL‐33 induces inflammatory gene signatures in eosinophils, characterised by the upregulation of cell surface markers, inflammatory mediators and regulatory factors, all of which were also observed in nasal polyp‐derived eosinophils. Ox‐LDL and complement fragments (C3a and C5a) promote eosinophil adhesion and survival.
Emiko Matsuyama, Jun Miyata, Takao Mochimaru, Ryuta Onozato, Yo Otsu, Hisashi Sasaki, Keeya Sunata, Shinichi Okuzumi, Katsunori Masaki, Hiroki Kabata, Keinosuke Hizuka, Yoshinori Hasegawa, Ryo Konno, Yusuke Kawashima, Makoto Arita, Shigeharu Ueki, Koichi Fukunaga   +16 more
wiley   +1 more source

Wells syndrome: clinical findings and management in a large cohort of 48 patients

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and Objectives: Wells syndrome (WS) is a rare inflammatory skin disorder typically characterized by erythematous, edematous, and pruritic plaques. Despite its distinct histopathological features, WS remains an underdiagnosed disease due to its variable clinical presentations and overlap with other dermatological conditions.
Marco Adriano Chessa, Silvia Robuffo, Tullio Brunetti, Luca Rapparini, Bianca Maria Piraccini, Cosimo Misciali, Beatrice Raone, Iria Neri, Federica Filippi   +8 more
wiley   +1 more source

Activated sputum eosinophils associated with exacerbations in children on mepolizumab.

Journal of Allergy and Clinical Immunology
BACKGROUND MUPPITS-2 was a randomized, placebo-controlled clinical trial that demonstrated mepolizumab (anti-interleukin-5) reduced exacerbations and blood and airway eosinophils in urban children with severe eosinophilic asthma.
Gabriella Wilson, J. Knight, Qing Liu, A. Shelar, Emma Stewart, Xiaomei Wang, Xiting Yan, J. Sanders, C. Visness, M. Gill, R. Gruchalla, Andrew H. Liu, M. Kattan, G. Hershey, A. Togias, P. Becker, Matthew C. Altman, William W. Busse, Daniel J. Jackson, R. Montgomery, Geoffrey L. Chupp   +20 more
semanticscholar   +1 more source

The Global Airways in Practice: Long‐term Effects of Mepolizumab With or Without FESS on Type 2 Inflammation in Patients With CRSwNP

International Forum of Allergy &Rhinology, Volume 16, Issue 4, Page 369-379, April 2026.
ABSTRACT Background Chronic rhinosinusitis with nasal polyps (CRSwNP) is a type 2 inflammatory disease often associated with asthma. The global airway hypothesis suggests bidirectional inflammatory interactions between upper and lower airways. Mepolizumab, an anti–IL‐5 therapy, treats conditions systemically, while functional endoscopic sinus surgery ...
Jens Tidemandsen, Vibeke Backer, Anne Sophie Homøe, Thomas H. L. Jensen, Kasper Aanæs, Howraman Meteran, Morten Hostrup, Lukas Moesgaard, Christiane Haase, Peter G. Gibson   +9 more
wiley   +1 more source

Long-Term Clinical and Sustained REMIssion in Severe Eosinophilic Asthma treated with Mepolizumab: The REMI-M study.

Journal of Allergy and Clinical Immunology: In Practice
BACKGROUND Biological therapies, such as mepolizumab, have transformed the treatment of severe eosinophilic asthma. While mepolizumab's short-term effectiveness is established, there is limited evidence on its ability to achieve long-term clinical ...
C. Crimi, S. Nolasco, Alberto Noto, A. Maglio, V. Quaranta, D. Di Bona, G. Scioscia, F. Papia, M. Caiaffa, Cecilia Calabrese, M. D’Amato, C. Pelaia, R. Campisi, C. Vitale, Luigi Ciampo, S. Dragonieri, Elena Minenna, Federica Massaro, L. Gallotti, L. Macchia, Massimo Triggiani, Nicola Scichilone, G. Valenti, G. Pelaia, M. F. Foschino Barbaro, G. E. Carpagnano, A. Vatrella, Nunzio Crimi, Morena Porto, P. Impellizzeri, Valentina Frazzetto, Martina Bonsignore, Concetta Giannì, A. Nardo, Fabio Vignera, Maria Teresa Busceti, N. Lombardo, D. Lacedonia, Pasquale Tondo, Piera Soccio, Carla Maria Irene Quarato, Francesca Montagnolo, Vittorio Salerno, Leonardo Maselli, Ernesto Julai, Francesco Coppa, L. Grimaldi, Isabella Carrieri, Alessio Sola, Marco Balestrino, D. F. Mariniello, A. Benfante, G. Spadaro, Aikaterini Detoraki, Luisa Ricciardi, Franzese Antonio, Longobardi Valeria   +56 more
semanticscholar   +2 more sources

Cost-effectiveness analysis of the use of mepolizumab in omalizumab-resistant patients with severe asthma

Качественная клиническая практика, 2019
Objective. To determine the clinical and economic consequences of the drug mepolizumab in patients with severe bronchial asthma (SBA) and the ineff ectiveness of omalizumab. Methods.
A. G. Tolkushin, V. A. Rogov, D. A. Ivanov, N. L. Pogudina   +3 more
doaj   +1 more source

Use of Modeling and Simulation to Inform the Development of Monoclonal Antibodies to Treat Moderate‐to‐Severe Asthma: A Retrospective Review of EMA Centralized Procedure From 2014 to 2024

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 4, April 2026.
ABSTRACT We present here a repository of key regulatory questions answered in centralized procedures and evaluate the place of modeling and simulation in marketing authorization process for biologics approved for the treatment of moderate‐to‐severe asthma from 2014 to 2024.
Hélène Haguet, Jean‐Michel Dogné, Flora T Musuamba   +2 more
wiley   +1 more source

Real-world characteristics and disease burden of patients with asthma prior to treatment initiation with mepolizumab or omalizumab: a retrospective cohort database study

Journal of Asthma and Allergy, 2019
Jean-Pierre Llanos,1 Christopher F Bell,1 Elizabeth Packnett,2 Ellen Thiel,2 Debra E Irwin,2 Beth Hahn,1 Hector Ortega3 1Respiratory, US Medical Affairs, GSK, Research Triangle Park, NC, USA; 2Truven Health Analytics, An IBM Watson Health Company, Ann ...
Llanos JP, Bell CF, Packnett E, Thiel E, Irwin DE, Hahn B, Ortega H   +6 more
doaj  

Clinical Evidence of the Use of Mepolizumab in the Treatment of Chronic Rhinosinusitis with Nasal Polyps: A Prospective Observational Study

Healthcare
Background/Objectives: Chronic rhinosinusitis with nasal polyps (CRSwNP) poses significant therapeutic challenges. The introduction of Mepolizumab, an anti-interleukin-5 monoclonal antibody, offers a new therapeutic option for patients with severe ...
A. Moffa, Francesco Iafrati, Lucrezia Giorgi, Domiziana Nardelli, L. Carnuccio, Peter M. Baptista, E. Olszewska, Manuele Casale   +7 more
semanticscholar   +1 more source

Relapse of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Despite Maintenance Treatment With Low‐Dose Mepolizumab

Respirology Case Reports
We present the case of an ANCA+ EGPA patient with a long disease history and remission for over 8 years (between 2015 and 2023), who developed a life‐threatening relapse marked by diffuse alveolar haemorrhage and mononeuritis multiplex despite low dose ...
Aurelie Vanthuyne, S. Riemann, G. Brusselle   +2 more
semanticscholar   +1 more source